[ad_1]
LONDON – The European Medicines Regulatory Agency has recommended the approval of the first dengue vaccine despite concerns over its widespread use and a lawsuit in the Philippines alleging that it was linked to three deaths.
The European Medicines Agency announced Friday that it has adopted a "positive opinion" on the Dengvaxia of the French pharmaceutical group Sanofi. This vaccine is the first in the world to fight dengue fever, which affects about 96 million people a year.
Earlier this year, the World Health Organization declared that the vaccine should be treated "much safer" and that it should be administered primarily to people who already have dengue fever. The vaccine is registered for use in approximately 20 countries.
Sanofi had previously warned that people who had never had dengue fever risked getting a more serious illness after receiving the vaccine.
Copyright 2018 The Associated Press. All rights reserved. This material may not be published, disseminated, rewritten or redistributed.
[ad_2]
Source link
